A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02670096

Enrollment

Registered

2016-02-01

Start date

2016-01-31

Completion date

2017-03-31

Last updated

2017-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea

Keywords

acetazolamide, Treatment Emergent Sleep Disordered Breathing, Sleep Apnea

Brief summary

This is a single center pilot study evaluating the immediate effects of low-dose acetazolamide on respiratory control in subjects with treatment emergent sleep disordered breathing. The purpose of this study is to assess the immediate effect one-time low-dose acetazolamide on sleep breathing in (Treatment Emergent Sleep Disordered Breathing) TE-CSA subjects compared to subjects' baseline evaluation without acetazolamide. Investigators will also try to determine the immediate effect of one-time low-dose acetazolamide on subjects' resting ventilation and ventilatory response slope compared to subjects' baseline evaluation without acetazolamide.

Interventions

DRUGAcetazolamide

Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age ≥18 to 80 years * TE-CSA * Subjects are capable of giving informed consent

Exclusion criteria

* Hypersensitivity to acetazolamide or other sulfonamides * Intake of carbonic anhydrase inhibitors within the last 72 hours * Intake of medication that influences breathing, sleep, arousal or muscle physiology * Cheyne-Stokes respiration * Heart failure * Renal failure * Liver failure * Chronic hypercapnea * Hyponatremia * Hypokalemia * Pregnancy * Breastfeeding mothers * Active drug/alcohol dependence or abuse history

Design outcomes

Primary

Measure	Time frame
Severity of Obstructive Sleep Apnea before and after acetazolamide administration using Laboratory Nocturnal Polysomnography	60 Days
Total lung capacity before and after acetazolamide administration	60 Days

Secondary

Measure	Time frame
Gas composition with and without acetazolamide using Resting Ventilation Study (RVS)	20 Minutes
Measure of ventilatory response to carbon dioxide (CO2) without and with acetazolamide	15 Minutes
Measurement of Arterial Blood Gas (ABG)	60 Days
Measurement of Venous Blood (VB) Analysis	60 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026